TMC LIFE SCIENCES BHD
KLSE (MYR): TMCLIFE (0101)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.53
Today's Change
0.00 (0.00%)
Day's Change
0.53 - 0.53
Trading Volume
63,900
Financial
Market Cap
Market Cap
923 Million
NOSH
1,742 Million
Latest Quarter
Latest Quarter
30-Jun-2024 [#4]
Announcement Date
21-Aug-2024
Next Quarter
30-Sep-2024
Est. Ann. Date
14-Nov-2024
Est. Ann. Due Date
29-Nov-2024
QoQ | YoY
-89.72% | -92.27%
T4Q Result
Revenue | NP to SH
346,418.000 | 40,648.000
RPS | P/RPS
19.89 Cent | 2.66
EPS | P/E | EY
2.33 Cent | 22.71 | 4.40%
DPS | DY | Payout %
2.22 Cent | 4.19% | 95.13%
NAPS | P/NAPS
0.51 | 1.04
QoQ | YoY
-23.12% | 3.54%
NP Margin | ROE
11.73% | 4.58%
F.Y. | Ann. Date
30-Jun-2024 | 21-Aug-2024
Latest Audited Result
Latest Audited Result
30-Jun-2024
Announcement Date
08-Oct-2024
Next Audited Result
30-Jun-2025
Est. Ann. Date
08-Oct-2025
Est. Ann. Due Date
27-Dec-2025
Annual (Unaudited)
Revenue | NP to SH
346,418.000 | 40,648.000
RPS | P/RPS
19.89 Cent | 2.66
EPS | P/E | EY
2.33 Cent | 22.71 | 4.40%
DPS | DY | Payout %
2.22 Cent | 4.19% | 95.13%
NAPS | P/NAPS
0.51 | 1.04
YoY
3.54%
NP Margin | ROE
11.73% | 4.58%
F.Y. | Ann. Date
30-Jun-2024 | 21-Aug-2024
Annualized Result
Revenue | NP to SH
346,418.000 | 40,648.000
RPS | P/RPS
19.89 Cent | 2.66
EPS | P/E | EY
2.33 Cent | 22.71 | 4.40%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
-23.06% | 3.54%
NP Margin | ROE
11.73% | 4.58%
F.Y. | Ann. Date
30-Jun-2024 | 21-Aug-2024
Business Process
| Trailing 4 Quarters | Trailing 8 Quarters | |||
|---|---|---|---|---|
| Available Quarters | 4 Quarters | 8 Quarters | ||
| Continuous Quarters Of Revenue Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Total Positive Profit Years | 4 / 4 | 100.00% | 8 / 8 | 100.00% |
| Continuous Quarters Of Positive Profit | 4 / 4 | 100.00% | 8 / 8 | 100.00% |
| Continuous Quarters Of Profit Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted EPS Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Total Dividend Years | 1 / 4 | 25.00% | 2 / 8 | 25.00% |
| Continuous Quarters Of Dividend | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Average ROE | 1.16% | 1.16% | ||
| Average Net Profit Margin | 11.21% | 11.77% | ||
| Last 5 Financial Years | Last 10 Financial Years | |||
|---|---|---|---|---|
| Available Years | 5 Years | 10 Years | ||
| Continuous Quarters Of Revenue Growth | 4 / 5 | 80.00% | 4 / 10 | 40.00% |
| Total Positive Profit Years | 5 / 5 | 100.00% | 9 / 10 | 90.00% |
| Continuous Quarters Of Positive Profit | 5 / 5 | 100.00% | 6 / 10 | 60.00% |
| Continuous Quarters Of Profit Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Continuous Quarters Of Adjusted EPS Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Total Dividend Years | 5 / 5 | 100.00% | 9 / 10 | 90.00% |
| Continuous Quarters Of Dividend | 5 / 5 | 100.00% | 6 / 10 | 60.00% |
| Continuous Quarters Of Dividend Growth | 4 / 5 | 80.00% | 4 / 10 | 40.00% |
| Continuous Quarters Of Adjusted Dps Growth | 4 / 5 | 80.00% | 4 / 10 | 40.00% |
| Average ROE | 3.71% | 3.23% | ||
| Average Net Profit Margin | 12.01% | 12.18% | ||
Key Result
| T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
|---|---|---|---|---|---|
| Revenue | 346,418 | 346,418 | 346,418 | 190,322 | 251,213 |
| NP to SH | 40,648 | 40,648 | 40,648 | 25,488 | 30,964 |
| Dividend | 38,669 | 38,669 | 38,669 | 7,707 | 12,994 |
| Adjusted EPS | 2.33 | 2.33 | 2.33 | 1.46 | 1.78 |
| Adjusted DPS | 2.22 | 2.22 | 2.22 | 0.44 | 0.75 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
Growth
| LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
|---|---|---|---|---|---|
| Revenue | -13.88% | -12.44% | 11.23% | -14.41% | -9.86% |
| NP to Owner | -89.72% | -92.27% | 3.54% | -89.92% | -89.75% |
| Dividend | 0.00% | 164.29% | 164.29% | 300.00% | 480.39% |
| Adjusted EPS | -89.47% | -92.11% | 3.56% | -89.70% | -89.54% |
| Adjusted DPS | 0.00% | 164.29% | 164.29% | 300.00% | 480.39% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
| T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00% | 37.90% | 82.02% | 0.00% | 37.90% | 82.02% | 11.23% | 37.90% | 82.02% |
| NP to Owner | 0.00% | 31.27% | 59.48% | 0.00% | 31.27% | 59.48% | 3.54% | 31.27% | 59.48% |
| Dividend | 0.00% | 197.59% | 401.71% | 0.00% | 197.59% | 401.71% | 164.29% | 197.59% | 401.71% |
| Adjusted EPS | 0.00% | 31.19% | 59.33% | 0.00% | 31.19% | 59.33% | 3.56% | 31.19% | 59.33% |
| Adjusted DPS | 0.00% | 197.59% | 401.71% | 0.00% | 197.59% | 401.71% | 164.29% | 197.59% | 401.71% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
Discussions
11 people like this. Showing 50 of 4,398 comments
New wing started to contribute to the financial result. As time goes, significant improvement will show very soon.
2022-08-24 07:14
Less men more share then? Contrarian approach? Perhaps another takeover target.
2023-12-13 23:10
Bot enough, start to promote.
https://klse.i3investor.com/web/blog/detail/sinchew_company_story/2024-01-01-story-h-211423465
2024-01-01 22:51
Alpha IVF listing with RM1.5 billion valuation soon,i think TMC was very much undervalued at current price.
2024-03-02 01:13
Beside IVF business which is recovering strongly,TMC also owned Thomson Hospital Kota Damansara,a premium hospital with 336 operating bed currently and maximum capacity of 554 bed when fully utilized the new wing by 2026.
2024-03-02 01:22
my personal opinion, TMC should worth around RM2 .0 to 2.4 billion based on FY2024 EV/Ebitda of 18-20x，the target valuation consider quite conservative given the rapid capacity expansion and high growth potential in next 5 year.
2024-03-02 01:31
Price did not react much to the 2nd letter to the suspended CEO. It looks good.
2024-05-07 13:14
With the existing 314 medical beds, the hospital segment generated RM 82 million in a quarter. TMC would increase quantity of bed to 394 (in Kota Damansara) by Jun 2024. Expect revenue up by RM 20 million per quarter for extra 80 beds.
2024-05-23 12:20
Potential of leap in revenue growth until 2027 with the medical beds capacity 554 units. TMC has added 80 medical bed in 2024 and follow by 80 units each for year 2025 and 2026.
2024-05-23 12:33
According tot the annual report, it will only commence construction after RTS starts running
2024-06-13 14:45
展望下半年，目前马股可谓利好环绕，获经济展望强稳、企业获利复苏、资金回流等因素加持，交投料保持活络，可望延续上半年强势。选股方面，笔者相对看好消费、建筑及科技股，整体料在利好加持下表现可期。
配合半年检讨，笔者决定对神通科技（SCOMNET,0001,创业板医疗保健组）和优宾机构（EUPE,6815,主机板产业组）进行套利，同时对TMC生命科学（TMCLIFE,0101,主机板医疗保健组）停损。
2024-07-01 11:20
Ann. Date Ex Date Type Subject Amount
21-Aug-2024 05-Dec-2024 DIVIDEND Special Dividend RM 0.0172
21-Aug-2024 05-Dec-2024 DIVIDEND Final Dividend RM 0.0048
The Board of Directors of the Company is proposing a single-tier final dividend of 0.4898 sen per ordinary share and a special single-tier dividend of 1.7271 sen per ordinary share for the financial year ended 30 June 2024 subject to the shareholders' approval at the forthcoming Twenty-Second Annual General Meeting of the Company.
This announcement is dated 21 August 2024.
2 months ago
Post a Comment
Featured Posts
Latest Videos
MQ Trading Signals
Time
Signal
Duration
Type
2024-11-05 09:20:00
EMA 5
10 Mins
BUY
2024-11-05 09:00:00
EMA 5
5 Mins
BUY
Apps
Top Articles
1
2
Stockhistory
4
BFM Podcast
6
BFM Podcast
7
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
money888
results will be better and better only....with new wing opening, more bed capacity, more revenue and profit
2022-02-10 13:09